Modality
Multispecific
MOA
CDK2i
Target
FcRn
Pathway
Amyloid
MDDET
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Jan 2027
Phase 2Current
NCT04943550
995 pts·MDD
2018-07→2027-01·Terminated
995 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2310mo awayPh3 Readout· MDD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Termina…
Catalysts
Ph3 Readout
2027-01-23 · 10mo away
MDD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04943550 | Phase 2/3 | MDD | Terminated | 995 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn |